SwePub
Sök i LIBRIS databas

  Extended search

L773:0016 5085 OR L773:1528 0012
 

Search: L773:0016 5085 OR L773:1528 0012 > Högskolan Dalarna > Association between...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Association between proton pump inhibitor use and risk of progression of chronic kidney disease

Klatte, Derk C F (author)
Gasparini, Alessandro (author)
Karolinska Institutet
Xu, Hong (author)
Karolinska Institutet
show more...
de Deco, Pietro (author)
Trevisan, Marco (author)
Karolinska Institutet
Johansson, Anna L V (author)
Karolinska Institutet
Wettermark, Björn (author)
Karolinska Institutet
Ärnlöv, Johan, 1970- (author)
Karolinska Institutet,Högskolan Dalarna,Medicinsk vetenskap,Uppsala universitet
Janmaat, Cynthia J (author)
Carrero, Juan J (author)
Karolinska Institutet
Lindholm, B (author)
Karolinska Institutet
Dekker, FW (author)
Coresh, J (author)
Grams, ME (author)
show less...
 (creator_code:org_t)
Elsevier BV, 2017
2017
English.
In: Gastroenterology. - : Elsevier BV. - 0016-5085 .- 1528-0012. ; 153:3, s. 702-710
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BACKGROUND & AIMS: Proton pump inhibitors (PPI) have been associated with acute kidney injury (AKI) and recent studies suggest that they may be associated with the risk of chronic kidney disease (CKD).METHODS: We performed a retrospective analysis using the Stockholm creatinine measurements database, which contains information on diagnoses, dispensation claims, and laboratory test results for all citizens in the Stockholm region from 2007 through 2010. We identified new users of PPIs (n= 105305) and new users of H2 blockers (H2B; n= 9578); data on renal outcomes were collected for a median 2.7 years. The primary outcome was progression CKD, defined as doubling of creatinine or decrease in estimated glomerular filtration rate of 30% or more. Secondary outcomes were end-stage renal disease and acute kidney injury (AKI). Complete collection of repeated PPI and H2B dispensations at pharmacies in Sweden allowed modeling the time-dependent risk associated to cumulative PPI exposure.RESULTS: Users of PPIs, compared to users of H2Bs, had an increased risk for doubled levels of creatinine (1985 events; adjusted hazard ratio [HR], 1.26; 95% CI, 1.05-1.51) and decrease in estimated glomerular filtration rate of 30% or more (11045 events; 1.26; 95% CI, 1.16-1.36). PPI use also associated with development of end-stage renal disease (HR, 2.40; 0.76-7.58) and AKI (HR, 1.30; 95% CI, 1.00-1.69). There was a graded association between cumulative exposure to PPIs and risk of CKD progression. This was not the case for cumulative H2B use.CONCLUSIONS: Initiation of PPI therapy and cumulative PPI exposure associate with increased risk of CKD progression in a large, North European healthcare system. Although consistent, the association was modest in magnitude, and cannot exclude residual confounding.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Keyword

SCREAM
eGFR
omeprazole
pharmacoepidemiology
Hälsa och välfärd
Health and Welfare

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view